Inmune Bio, Inc. (INMB): Total Liabilities
$8.83M
As of 2025-12-31
$6.48M
As of 2026-06-30
-25.9%
3-year compound annual growth
+35.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.83M | +18.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $7.46M | -60.4% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $18.86M | -13.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $21.69M | +10.0% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $19.72M | +936.8% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $1.90M | +121.0% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $860.5K | +4.5% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $823.8K | +166.0% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $309.7K | n/a | 2019-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $8.83M | +18.2% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $2.89M | +120.8% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $15.56M | +56.7% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $45.63M | -3.1% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $8.48M | +104.1% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $2.16M | -21.9% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $284.9K | -13.1% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $16.50M | +15.8% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $19.84M | +13.7% |
Compare INMB, ENTX, AIM, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗